| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4797 | 2017 |
| ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ... Biology of blood and marrow transplantation 25 (4), 625-638, 2019 | 2184 | 2019 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1879 | 2019 |
| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017 | 1462 | 2017 |
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ... Journal of clinical oncology 32 (21), 2240-2247, 2014 | 770 | 2014 |
| Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, ... Molecular Therapy 25 (1), 285-295, 2017 | 661 | 2017 |
| NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment WY Go, X Liu, MA Roti, F Liu, SN Ho Proceedings of the National Academy of Sciences 101 (29), 10673-10678, 2004 | 330 | 2004 |
| Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, ... Blood advances 4 (19), 4898-4911, 2020 | 276 | 2020 |
| Expression of podocalyxin inhibits cell–cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells T Takeda, WY Go, RA Orlando, MG Farquhar Molecular biology of the cell 11 (9), 3219-3232, 2000 | 269 | 2000 |
| Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) FL Locke, SS Neelapu, NL Bartlett, LJ Lekakis, CA Jacobson, ... Blood 130, 1547, 2017 | 157 | 2017 |
| SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type … JR Hecht, A Cohn, S Dakhil, M Saleh, B Piperdi, M Cline-Burkhardt, ... Clinical colorectal cancer 14 (2), 72-80, 2015 | 122 | 2015 |
| Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy PH Chen, M Lipschitz, JL Weirather, C Jacobson, P Armand, K Wright, ... JCI insight 5 (12), 2020 | 78 | 2020 |
| Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1 SS Neelapu, FL Locke, NL Bartlett, L Lekakis, D Miklos, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 128 (22), LBA-6-LBA-6, 2016 | 76 | 2016 |
| Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in … JC Bendell, CE Atreya, T Andre, J Tabernero, MS Gordon, R Bernards, ... Journal of Clinical Oncology 32 (15_suppl), 3515-3515, 2014 | 76 | 2014 |
| Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, H Yu, ... Journal of Clinical Oncology 31 (15_suppl), 3631-3631, 2013 | 61 | 2013 |
| Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene … J Galon, J Rossi, S Turcan, C Danan, FL Locke, SS Neelapu, DB Miklos, ... Journal of Clinical Oncology, 2017 | 56 | 2017 |
| Long-term follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, ED Jacobsen, ... Blood 130, 578, 2017 | 49 | 2017 |
| Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review FL Locke, WY Go, SS Neelapu JAMA oncology 6 (2), 281-290, 2020 | 47 | 2020 |
| Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin … FL Locke, SS Neelapu, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... Journal of Clinical Oncology 35 (15_suppl), 7512-7512, 2017 | 35 | 2017 |
| SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild … JR Hecht, AL Cohn, SR Dakhil, MN Saleh, B Piperdi, VJM Cline-Burkhardt, ... Journal of Clinical Oncology 31 (4_suppl), 454-454, 2013 | 30 | 2013 |
